Page 285«..1020..284285286287..290300..»

Midwest Book Review Recommends The Genius Gene, a Genetic Engineering Thriller … – NewsReleaseWire.com (press release)

By Dr. Matthew Watson


NewsReleaseWire.com (press release)
Midwest Book Review Recommends The Genius Gene, a Genetic Engineering Thriller ...
NewsReleaseWire.com (press release)
Taking place 40 years in the future, Birnberg's novels are, in part, designed up highlight the debate that will be taking place on genetic engineering by doctors, drug companies, parents, government bureaucrats and insurance companies. ...

To Read More: Midwest Book Review Recommends The Genius Gene, a Genetic Engineering Thriller … – NewsReleaseWire.com (press release)
categoriaUncategorized commentoComments Off on Midwest Book Review Recommends The Genius Gene, a Genetic Engineering Thriller … – NewsReleaseWire.com (press release) | dataJune 19th, 2011
Read All

HudsonAlpha announces expansion on biotechnology campus – WAFF

By Dr. Matthew Watson


al.com (blog)
HudsonAlpha announces expansion on biotechnology campus
WAFF
Governor Robert Bentley will be on hand Wednesday morning to acknowledge the state's ongoing dedication to the HudsonAlpha Institute for Biotechnology and expansion of the life sciences industry in Alabama. "The addition of a new facility on the ...
Gov. Robert Bentley takes part in latest HudsonAlpha groundbreakingal.com (blog)

all 3 news articles »

To Read More: HudsonAlpha announces expansion on biotechnology campus – WAFF
categoriaUncategorized commentoComments Off on HudsonAlpha announces expansion on biotechnology campus – WAFF | dataJune 19th, 2011
Read All

Size matters — in virulent fungal spores — and suggests ways to stop a killer – Science Daily (press release)

By Dr. Matthew Watson


Scientific American (blog)
Size matters -- in virulent fungal spores -- and suggests ways to stop a killer
Science Daily (press release)
Other authors include lead author Charles Li and Deborah Springer of the Duke Department of Molecular Genetics and Microbiology, Maria Cervantes of the Universidad de Murcia, and Teun Boekhout of the CBS-KNAW Fungal Biodiversity Centre in Utrecht, ...
Super-Sized Spores Make Fungal Infections More Deadly, Possibly Explaining ...Scientific American (blog)

all 5 news articles »

To Read More: Size matters — in virulent fungal spores — and suggests ways to stop a killer – Science Daily (press release)
categoriaUncategorized commentoComments Off on Size matters — in virulent fungal spores — and suggests ways to stop a killer – Science Daily (press release) | dataJune 19th, 2011
Read All

A New Look at Obsessive-Compulsive Disorder (preview)

By Dr. Matthew Watson

One day 12-year-old Elizabeth McIngvale became obsessed with the number 42, which happened to be her mother’s age at the time, 11 years ago. When she washed her hands, she had to turn the sink on and off 42 times, get 42 pumps of soap and rinse her hands 42 times. Sometimes she decided that she actually needed to do 42 sets of 42. When she dressed, she put her right leg in and out of her pant leg 42 times, then the left. Even getting up from a chair took 42 attempts. She was afraid that if she did not follow her self-prescribed ritual, something terrible would happen to her family--they might die in a car accident, for instance. “Everything I did was completely exhausting and grueling,” she recalls. “I was probably doing 12 to 13 hours a day of rituals.”

McIngvale was diagnosed with obsessive- compulsive disorder (OCD), a psychiatric illness that afflicts 2 to 3 percent of Americans, not all of them as severely as McIngvale. Individuals with OCD experience debilitating recurrent and persistent thoughts, or obsessions, which they try to suppress or eliminate with rituals, known as compulsions. Compared with people who have other anxiety or mood disorders, adults with OCD are more likely to be single and unemployed. In fact, OCD is among the 10 most disabling medical and psychiatric conditions.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


To Read More: A New Look at Obsessive-Compulsive Disorder (preview)
categoriaUncategorized commentoComments Off on A New Look at Obsessive-Compulsive Disorder (preview) | dataJune 19th, 2011
Read All

Autism’s Tangled Genetics Full of Rare and Varied Mutations

By Dr. Matthew Watson

The underpinnings of autism are turning out to be even more varied than the disease's diverse manifestations. In four new studies and an analysis published June 8 researchers have added some major landmarks in the complex landscape of the disease, uncovering clues as to why the disease is so much more prevalent in male children and how such varied genetic mutations can lead to similar symptoms. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


To Read More: Autism’s Tangled Genetics Full of Rare and Varied Mutations
categoriaUncategorized commentoComments Off on Autism’s Tangled Genetics Full of Rare and Varied Mutations | dataJune 19th, 2011
Read All

International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCOE) announced today that Donna Queen has joined ISCO's executive team. Ms. Queen will be primarily responsible for ISCO's wholly owned subsidiary Lifeline Skin Care's (Lifeline) brand identity and international marketing as well as broadening the range of Lifeline products currently available.


Prior to joining ISCO, Ms. Queen was President and CEO of ZO SKIN HEALTH® by Zein Obagi, MD. Dr. Obagi is the dermatologist who created the original Obagi Nu-Derm skincare system, which has since become the leading physician-dispensed brand of anti-aging skincare. Earlier Ms. Queen founded and led one of Virginia's largest advertising and marketing agencies, specializing in aesthetic and dermatological marketing and brand development.


Dr. Andrey Semechkin, President and CEO of ISCO, commented: "I'm very pleased that Ms. Queen has joined our team. Ms. Queen's industry experience and expertise particularly in marketing prescription-based products will be invaluable as we expand our skin care business and further enhance our line of products."


Ms. Queen adds, "I'm very excited to be joining such a dynamic, science-driven company. There have been no recent meaningful technological breakthroughs in skin care, but with ISCO's scientific leadership in stem cells and their knowledge of skin tissue physiology we have an opportunity to continue to deliver new and innovative treatments."


ISCO previously announced sales of approximately $1.1 million from the pilot direct-to-consumer launch of Lifeline's first two products, an anti-aging Day Serum and a Night Serum. These products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetics experts. The serums contain an extract from ISCO?s proprietary human parthenogenetic stem cells combined with antioxidants and botanically derived ingredients. Using these serums on a regular basis provides significant benefits to the skin including improvement in skin tone and elasticity and the improvement in the appearance of fine lines and wrinkles, results that have been independently established by clinical studies performed at industry-leading testing laboratories. The serums can be purchased by visiting Lifeline?s website at http://www.lifelineskincare.com and are also available at selected luxury spas and physicians' offices in the United States.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110616005464r1&sid=14230&distro=ftp
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO, Lifeline Skin Care
ras@intlstemcell.com

or
Simon Craw, PhD
Vice President, ISCO
sc@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

To Read More: International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team | dataJune 19th, 2011
Read All

International Stem Cell Corporation Discovers Method to Produce Uncontaminated Liver Cells: New Platform to Produce Various Cell Types Free From Undifferentiated, Potentially Tumorigenic, Cells

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCOE) announces the discovery of a novel, patent-pending technology to produce unlimited numbers of liver cells (hepatocytes) that are free of contamination with potentially dangerous undifferentiated cells. The technology is based on the natural, physiological properties of the cellular environment, and does not require any additional purification of the final product. The starting materials for the production are pluripotent stem cells, either ISCO's proprietary human parthenogenetic stem cells (hpSCs) or human embryonic stem cells (hESCs).


The technology is described in a new article that will appear in Cell Transplantation, the Regenerative Medicine Journal (currently the article is available only in electronic form). The published data also reinforce that hpSCs can provide the cellular material necessary for the implementation of cell-based therapies.


Marie Csete, M.D., Ph.D., co-author of the paper, said, "Derivation of differentiated cell products that are not contaminated with undifferentiated cells solves a major technical roadblock in the development of all pluripotent stem cell-based therapies because undifferentiated stem cells with tumorigenic potential can persist through long differentiation protocols. Therefore methods to generate pure differentiated cells for transplantation are critical for creating successful cell therapies. Furthermore, the elegant technology developed by ISCO scientists to enforce critical steps in differentiation illustrates the power and importance of basic engineering tools in stem cell biology."


Nikolay Turovets, Ph.D., Director of Research and Therapeutic Development at ISCO and co-author of the paper stated, "The technology discovered by our research team is based on reproducing features of the normal human embryonic microenvironment. The method uses a differentiation device that incorporates a three-dimensional extracellular matrix, combined with a porous membrane. Treatment of undifferentiated cells above the membrane using differentiation-directed proteins results in permitting the desired cells to migrate through the membrane into the matrix, where they further differentiate into functional hepatocytes."


Jeffrey Fair, M.D., liver transplant surgeon and Director of Translational Research for the Cedars-Sinai Comprehensive Transplant Center and Department of Surgery in Los Angeles, and co-author of the paper said, "Derivatives of HLA-homozygous hpSCs are likely to be significantly less susceptible to immune rejection after transplantation, thus offering major advantages over other pluripotent cell sources of hepatocytes. In the paper, we demonstrated that hepatocytes derived from hpSCs in this differentiation system demonstrate activities that are missing in a number of metabolic liver diseases, such as expression of AAT and OTC genes. Thus, personalized HLA-matching, as well as presence of the required activities make the pure hepatocyte population derived from hpSCs an attractive development candidate for cell therapy of metabolic liver diseases, urea cycle disorders, AAT-deficiency or other liver diseases in which a single hepatocyte product can ameliorate disease."


The approach used to derive a pure hepatocyte population is a technology platform that may allow derivation of various cell populations from different sources.


Andrey Semechkin, Ph.D., President and CEO of ISCO, and co-author of the paper stated, "We have discovered technology that has a number of features and advantages, and our plans are to expand the applications of this platform to develop new products. This system is universal and does not depend of the particularities of cell lines. As such it could be successfully used with hpSCs, hESCs and, we believe, with induced pluripotent stem cells (iPSs). Because isolation of undifferentiated cells happens at the first step of the differentiation procedure, the technology could be used to isolate other cell types, for example pancreatic or heart cells. Also, because technology is based on a natural process, cell separation is accomplished without any cell damage, in contrast to physical purification methods such as FACS, or magnetic sorting."


An electronic pre-copy-edited version of the paper entitled "Derivation of high-purity definitive endoderm from human parthenogenetic stem cells using an in vitro analog of the primitive streak" is available at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0284agapova.


A color version of the paper will be available when the print publication is issued. Prior to print publication, color figures can be obtained upon request from Nikolay Turovets, PhD:nturovets@intlstemcell.com.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell lines, the potential applications and benefits of the new technology, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and new technologies, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110614005644r1&sid=14230&distro=ftp
International Stem Cell Corporation
760-940-6383
Kenneth C. Aldrich
Chairman
kaldrich@intlstemcell.com

or
Nikolay Turovets, Ph.D.
Director of Research and Therapeutic Development
nturovets@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley (dmarkley@lhai.com)
310-691-7100

To Read More: International Stem Cell Corporation Discovers Method to Produce Uncontaminated Liver Cells: New Platform to Produce Various Cell Types Free From Undifferentiated, Potentially Tumorigenic, Cells
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation Discovers Method to Produce Uncontaminated Liver Cells: New Platform to Produce Various Cell Types Free From Undifferentiated, Potentially Tumorigenic, Cells | dataJune 19th, 2011
Read All

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

By Dr. Matthew Watson


International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.

A webcast of the presentation will be accessible online at http://www.internationalstemcell.com, or the PrecisionIR event site: http://www.vcall.com/CustomEvent/lipper/index.aspAn archived version will be available for 30 days.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

To Read More: International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16
categoriaStem Cell Therapy commentoComments Off on International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16 | dataJune 19th, 2011
Read All

PROSTATE CANCER and stem cells.wmv

By Dr. Matthew Watson

ramirezdelrio.com Business entrepreneur Larry Howard's 77 year old father was in deep trouble. He had been diagnosed with metastatic prostate cancer by his doctors at Kaiser Permanente. Their treatments had failed to check it and it was spreading

The rest is here:
PROSTATE CANCER and stem cells.wmv

To Read More: PROSTATE CANCER and stem cells.wmv
categoriaUncategorized commentoComments Off on PROSTATE CANCER and stem cells.wmv | dataJune 18th, 2011
Read All

Stem Cell Therapy MS: Sam Harrell and The Superbowl

By Dr. Matthew Watson

Stem cell therapy enables legendary Ennis, Texas football coach to see his son in Super Bowl XLV

Continue reading here:
Stem Cell Therapy MS: Sam Harrell and The Superbowl

To Read More: Stem Cell Therapy MS: Sam Harrell and The Superbowl
categoriaUncategorized commentoComments Off on Stem Cell Therapy MS: Sam Harrell and The Superbowl | dataJune 17th, 2011
Read All

New ‘Apes’ film revisits old ideas in science – USA Today

By Dr. Matthew Watson


USA Today
New 'Apes' film revisits old ideas in science
USA Today
... the worry of the day, where the 1970's films touched on Cold War nuclear fears and equality in the post-Civil Rights era, and the new film revolves around modern apprehension with genetic engineering and animal testing of drugs, Wyatt acknowledges. ...

and more »

To Read More: New ‘Apes’ film revisits old ideas in science – USA Today
categoriaUncategorized commentoComments Off on New ‘Apes’ film revisits old ideas in science – USA Today | dataJune 12th, 2011
Read All

Center for Genetic Engineering and Biotechnology of Camagüey, an economic power – Radio Cadena Agramonet

By Dr. Matthew Watson


Radio Cadena Agramonet
Center for Genetic Engineering and Biotechnology of Camagüey, an economic power
Radio Cadena Agramonet
To favour through science the economic development of Cuba, is one of the main intentions of researchers that work in the Center for Genetic Engineering and Biotechnology of this province. Eulogio Pimentel, director of the institution, expressed that ...

To Read More: Center for Genetic Engineering and Biotechnology of Camagüey, an economic power – Radio Cadena Agramonet
categoriaUncategorized commentoComments Off on Center for Genetic Engineering and Biotechnology of Camagüey, an economic power – Radio Cadena Agramonet | dataJune 12th, 2011
Read All

Room to grow in RI now key to growth of biotechnology industry – Providence Journal

By Dr. Matthew Watson


Providence Journal
Room to grow in RI now key to growth of biotechnology industry
Providence Journal
But even if the old highway land is developed in a well-planned way, university and research experts say more must be done to generate growth in the state's biotechnology industry, a key piece of the new economy. Rhode Island needs an academic ...

To Read More: Room to grow in RI now key to growth of biotechnology industry – Providence Journal
categoriaUncategorized commentoComments Off on Room to grow in RI now key to growth of biotechnology industry – Providence Journal | dataJune 12th, 2011
Read All

Birch bark nutrient prevents obesity, diabetes and high cholesterol

By Dr. Matthew Watson

Researchers from the Shanghai Institutes for Biological Sciences (SIBC) in China have identified a powerful compound in birch bark called betulin that helps lower cholesterol and prevent both diabetes and obesity. And betulin works particularly better than the statin drug lovastatin at lowering cholesterol, except without the harmful side effects.

Dr. Bao-Liang Song and his colleagues from SIBC tested the effects of betulin and found that it specifically targets the genes responsible for making harmful blood fats like triglycerides by effectively lowering their activity and protecting against disease. And since the compound is "abundant in birch bark," it has the potential to revolutionize the way blood fat levels are managed.

Concerning cholesterol levels, betulin was shown to lower lipid levels more effectively than lovastatin. And insulin-wise, betulin helps keep artery walls free and clear of build-ups and blockages, also known as atherosclerosis. Read more...

Ayurtox for Body Detoxification

To Read More: Birch bark nutrient prevents obesity, diabetes and high cholesterol
categoriaIntegrative Medicine commentoComments Off on Birch bark nutrient prevents obesity, diabetes and high cholesterol | dataJune 5th, 2011
Read All

Mutated muscle protein paves way for deafness, claims research – HealthJockey.com

By Dr. Matthew Watson


HealthJockey.com
Mutated muscle protein paves way for deafness, claims research
HealthJockey.com
In a major breakthrough, researchers from the Max Planck Institute for Molecular Genetics in Berlin found a new genetic cause of progressive hearing impairment. They believe that mutations of the small muscle protein (SMPX) gene cause hearing ...
Gene mutations linked to progressive hearing impairmentNewstrack India

all 7 news articles »

To Read More: Mutated muscle protein paves way for deafness, claims research – HealthJockey.com
categoriaUncategorized commentoComments Off on Mutated muscle protein paves way for deafness, claims research – HealthJockey.com | dataJune 5th, 2011
Read All

Cancer drug may help cure common, inherited dementia – Daily News & Analysis

By Dr. Matthew Watson


NewsReleaseWire.com (press release)
Cancer drug may help cure common, inherited dementia
Daily News & Analysis
... of familial frontotemporal dementia (FTD), a progressive, inherited neurodegenerative disease for which there is no treatment," said Joachim Herz, professor of molecular genetics and neuroscience at UT Southwestern and the study's senior author. ...
Cancer drug holds promise as first treatment for common, inherited dementiaEurekAlert (press release)
Common, Inherited Dementia May Respond To Cancer DrugMedical News Today (press release)

all 21 news articles »

To Read More: Cancer drug may help cure common, inherited dementia – Daily News & Analysis
categoriaUncategorized commentoComments Off on Cancer drug may help cure common, inherited dementia – Daily News & Analysis | dataJune 5th, 2011
Read All

New TV spot and trailer for ‘Rise of the Planet of the Apes’ – Monsters and Critics.com

By Dr. Matthew Watson


USA Today
New TV spot and trailer for 'Rise of the Planet of the Apes'
Monsters and Critics.com
"Rise of the Planet of the Apes" is released across the US from August 5th and the UK from August 12th. Set in present day San Francisco, the film deals with the aftermath of genetic engineering experiments that lead to intelligence in apes and a war ...
'Rise of the Planet of the Apes' unmasks simiansUSA Today
Film trailer: new 'Rise of the Planet of the Apes' starring James FrancoThe Independent
Rise of the Planet of the Apes Trailer: When Monkeys Attack!The Hollywood Gossip
The Film Pilgrim -WorstPreviews.com -JOE
all 129 news articles »

To Read More: New TV spot and trailer for ‘Rise of the Planet of the Apes’ – Monsters and Critics.com
categoriaUncategorized commentoComments Off on New TV spot and trailer for ‘Rise of the Planet of the Apes’ – Monsters and Critics.com | dataJune 5th, 2011
Read All

Aretha Franklin dying from advanced pancreatic cancer, say reports

By Dr. Matthew Watson

The "Queen of Soul" Aretha Franklin has reportedly been given less than a year to live by her doctors. She is reportedly suffering from "incurable advanced pancreatic cancer" according to The National Inquirer, a source that should perhaps be taken with a grain of salt. But CBS News is also running the story, along with other mainstream media outlets.

The reason her cancer is "advanced," of course, is because her doctors never told her the truth about pancreatic cancer, which is that through significant changes in diet and lifestyle, even pancreatic cancer can be reversed. I've seen numerous pancreatic cancer patients who reversed their condition by turning to natural cancer therapies such as Gerson Therapy, which is based on daily juicing of fresh vegetables and fruit, cleansing detoxificatiohttp://www.blogger.com/img/blank.gifn of the body's organs, and improving the nutritional density of foods. (http://www.Gerson.org)

The cancer industry is terrified that people might discover these "natural cures" to cancer because this would wipe out the highly lucrative chemotherapy, radiation and surgical treatments that remain the profit centers for mainstream cancer treatment centers. There is a reason, after all, why U.S. authorities ran all the alternative cancer clinics out of the country and arrested the alternative doctors who were curing the most patients. Such cures simply cannot be allowed in America because they threaten the profits of the cancer industry! Read more...

Ayurtox for Body Detoxification

To Read More: Aretha Franklin dying from advanced pancreatic cancer, say reports
categoriaIntegrative Medicine commentoComments Off on Aretha Franklin dying from advanced pancreatic cancer, say reports | dataMay 29th, 2011
Read All

PU signs MoU with National Agri Food Biotechnology Institute – Indian Express

By Dr. Matthew Watson


India Education Diary
PU signs MoU with National Agri Food Biotechnology Institute
Indian Express
... a memorandum of understanding (MoU) with National Agri-Food Biotechnology Institute (NABI) — a constituent laboratory of Department of Biotechnology (DBT). The MoU was signed by PU Vice-Chancellor RC Sobti and NABI Executive Director Rakesh Tuli. ...
Panjab University signs a MoU with National Agri-FoodIndia Education Diary

all 2 news articles »

To Read More: PU signs MoU with National Agri Food Biotechnology Institute – Indian Express
categoriaUncategorized commentoComments Off on PU signs MoU with National Agri Food Biotechnology Institute – Indian Express | dataMay 29th, 2011
Read All

International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth…

By Dr. Matthew Watson

International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth of Research Product Sales

International Stem Cell Corporation (OTCBB: ISCO) (ISCO) announces that revenue in the first quarter of 2011 was $1.5 million, compared with revenue of $273,000 in the first quarter of 2010. The increase was primarily due to $1.1 million in sales of Lifeline Skin Care products achieved in the pilot direct-to-consumer launch. Adding to the revenue growth was a 35% increase over the prior year in sales of human cell culture research products from subsidiary Lifeline Cell Technology.

ISCO also disclosed that it is delaying the filing of its Report on Form 10-Q for the period ending March 31, 2011 in order to resolve an accounting question as described below.

Shortly before the scheduled date for filing the 10-Q, ISCO identified an issue related to whether a technical interpretation of certain accounting guidance found in FASB ASC Topic 815, Derivatives and Hedging could require a change in the manner ISCO has historically accounted for the value of warrants originally issued as compensation to brokers working for the placement agent in the Company's 2007 initial public offering.

The accounting question is highly technical in nature and would have no impact on cash or revenues, but relates solely to the non-cash accounting for warrants issued several years ago. Rather than publish information that might be subject to further revision, ISCO has elected to delay the filing of its 10-Q until a decision can be made as to whether or not adjustments will need to be made and, if so, exactly what the accounting entries will be. The Company is committed to resolving this question as promptly as possible and will disclose the conclusion in the 10-Q.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, anticipated resolution of the accounting question, and opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, the application of accounting guidance, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110525005411r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

To Read More: International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth…
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth… | dataMay 29th, 2011
Read All

Page 285«..1020..284285286287..290300..»


Copyright :: 2025